[Idiopathic thrombocytopenic purpura].
Kuwana
Masataka
M
Institute for Advanced Medical Research, Keio University School of Medicine.
D000069594:Abatacept; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D001323:Autoantibodies; D001792:Blood Platelets / Q000276:immunology; D015195:Drug Design; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010980:Platelet Membrane Glycoproteins / Q000276:immunology; D011379:Prognosis; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D010980:Platelet Membrane Glycoproteins; D000074323:Alemtuzumab; D000069283:Rituximab; D000069594:Abatacept